TELA Bio, Inc.
$0.63
▲
5.01%
2026-04-21 09:46:01
www.telabio.com
NGM: TELA
Explore TELA Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$30.55 M
Current Price
$0.63
52W High / Low
$2.2 / $0.5
Stock P/E
—
Book Value
$0.14
Dividend Yield
—
ROCE
-53.21%
ROE
-2.23%
Face Value
—
EPS
$-0.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
—
Beta
0.99
Debt / Equity
913.26
Current Ratio
4.21
Quick Ratio
3.59
Forward P/E
-1.01
Price / Sales
0.32
Enterprise Value
$32.19 M
EV / EBITDA
-0.98
EV / Revenue
0.4
Rating
None
Target Price
$2.25
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lifeward Ltd. | $7.52 | — | $11.49 M | — | -155.52% | -1.46% | $18.6 / $4.14 | $5.52 |
| 2. | Pacific Biosciences of California, Inc. | $1.74 | — | $510.38 M | — | -78.39% | -2.13% | $2.73 / $0.85 | $0.02 |
| 3. | STERIS plc | $223.73 | 31.17 | $21.95 B | 1.11% | 10.53% | 10.47% | $269.44 / $209.98 | $72.93 |
| 4. | NovoCure Limited | $12.67 | — | $1.44 B | — | -26.47% | -38.89% | $20.06 / $9.82 | $3.03 |
| 5. | Integra LifeSciences Holdings Corporation | $11.16 | — | $875.54 M | — | 0.57% | -39.9% | $17.54 / $8.7 | $13.4 |
| 6. | Profound Medical Corp. | $7.15 | — | $331 M | — | -57.78% | -67.11% | $12.4 / $5.23 | $1.83 |
| 7. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 20.87 M | 20.69 M | 20.2 M | 18.52 M | 17.65 M | — |
| Operating Profit | -6.65 M | -7.55 M | -9.08 M | -10.47 M | -8.35 M | — |
| Net Profit | -9.04 M | -8.6 M | -9.92 M | -11.26 M | -9.21 M | — |
| EPS in Rs | -0.2 | -0.19 | -0.22 | -0.25 | -0.21 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 80.28 M | 69.3 M | 58.45 M | 41.42 M |
| Operating Profit | -33.76 M | -41.7 M | -44.08 M | -39.01 M |
| Net Profit | -38.83 M | -37.84 M | -46.66 M | -44.3 M |
| EPS in Rs | -0.87 | -0.85 | -1.04 | -0.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 81.42 M | 86.57 M | 78.05 M | 67.86 M |
| Total Liabilities | 75.11 M | 58.11 M | 59.17 M | 53.55 M |
| Equity | 6.31 M | 28.46 M | 18.88 M | 14.3 M |
| Current Assets | 75.58 M | 78.07 M | 71.73 M | 62.45 M |
| Current Liabilities | 17.98 M | 15.6 M | 16.97 M | 12.4 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -28.22 M | -41.59 M | -40.86 M | -40.75 M |
| Investing CF | 0.85 M | 4.45 M | -0.6 M | -1.87 M |
| Financing CF | 25.75 M | 43.06 M | 46.27 M | 40.85 M |
| Free CF | -28.67 M | -42.58 M | -41.47 M | -42.62 M |
| Capex | -0.45 M | -0.99 M | -0.61 M | -1.87 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 18.56% | 41.13% | — | — |
| Earnings Growth % | 18.91% | -5.35% | — | — |
| Profit Margin % | -54.6% | -79.83% | -106.95% | — |
| Operating Margin % | -60.17% | -75.4% | -94.18% | — |
| Gross Margin % | 67.08% | 68.62% | 65.3% | — |
| EBITDA Margin % | -45.72% | -69.51% | -94.3% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.